Skip to main content
. Author manuscript; available in PMC: 2019 Nov 14.
Published in final edited form as: Cell Host Microbe. 2018 Nov 14;24(5):717–730.e5. doi: 10.1016/j.chom.2018.10.012

Figure 1. Longitudinal neutralizing antibody responses of two subjects with HCV clearance and a third with persistence of infection.

Figure 1.

(A) HCV RNA was measured at initial infection and then periodically for more than six years. Dashed line indicates limit of detection (LOD) of the HCV RNA assay. (B) Neutralizing breadth of longitudinal plasma samples or bNAbs HEPC3 and HEPC98 (isolated from C117), bNAbs HEPC74 and HEPC43 (isolated from C110), or CBH-2 (control bNAb). Values are the number out of nineteen HCVpp neutralized at least 50% by a 1:50 dilution of plasma, or by 10 μg/mL of mAb, tested in duplicate. (C) Spearman correlations were measured between neutralization profiles (i.e., patterns of relative neutralization potency across a panel of 19 HCV strains) of C117 or C110 plasma samples and autologous or negative control (CBH-2) bNAbs (see also Fig S1). Significant r values are colored with a yellow to green heatmap.